Your browser is no longer supported. Please, upgrade your browser.
Rigel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.09 Insider Own0.21% Shs Outstand170.89M Perf Week-10.94%
Market Cap372.14M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float170.64M Perf Month-12.31%
Income-14.50M PEG- EPS next Q-0.13 Inst Own83.30% Short Float8.64% Perf Quarter-31.74%
Sales147.30M P/S2.53 EPS this Y55.90% Inst Trans-0.01% Short Ratio9.10 Perf Half Y-46.35%
Book/sh0.29 P/B7.86 EPS next Y-388.90% ROA-8.10% Target Price7.83 Perf Year-39.68%
Cash/sh0.88 P/C2.60 EPS next 5Y- ROE-25.20% 52W Range2.22 - 5.50 Perf YTD-13.96%
Dividend- P/FCF45.38 EPS past 5Y21.20% ROI-53.90% 52W High-57.45% Beta1.45
Dividend %- Quick Ratio2.80 Sales past 5Y30.30% Gross Margin99.40% 52W Low5.41% ATR0.16
Employees169 Current Ratio2.90 Sales Q/Q16.80% Oper. Margin-6.70% RSI (14)41.58 Volatility7.40% 5.81%
OptionableYes Debt/Eq0.40 EPS Q/Q-46.10% Profit Margin-9.90% Rel Volume0.78 Prev Close2.28
ShortableYes LT Debt/Eq0.40 EarningsNov 02 AMC Payout- Avg Volume1.62M Price2.34
Recom1.70 SMA20-9.21% SMA50-12.90% SMA200-33.36% Volume1,189,925 Change2.63%
Nov-09-20Downgrade JP Morgan Overweight → Neutral
Nov-15-19Resumed Cantor Fitzgerald Overweight $7 → $5
Sep-26-19Resumed JP Morgan Overweight $7
Mar-01-19Reiterated Cantor Fitzgerald Overweight $9 → $7
Aug-27-18Initiated Citigroup Buy $8.50
May-02-18Reiterated Cantor Fitzgerald Overweight $6 → $9
Dec-21-17Resumed Piper Jaffray Overweight $6
Dec-15-17Initiated Cantor Fitzgerald Overweight $6
Nov-06-17Resumed H.C. Wainwright Buy $7
Mar-09-17Reiterated H.C. Wainwright Buy $6 → $5
Aug-31-16Reiterated H.C. Wainwright Buy $6 → $7
Aug-30-16Reiterated Piper Jaffray Overweight $10 → $11
Jul-13-16Initiated H.C. Wainwright Buy $6
Jun-13-16Initiated Piper Jaffray Overweight
Apr-22-16Upgrade JP Morgan Neutral → Overweight
Apr-08-13Reiterated Stifel Buy $11 → $7
Nov-29-12Initiated UBS Neutral $9
Nov-06-12Reiterated Oppenheimer Outperform $12 → $15
Mar-26-12Initiated Canaccord Genuity Hold $8
Dec-10-10Downgrade MP Advisors Outperform → Market Perform
Jan-17-22 09:46AM  
Jan-12-22 01:29PM  
Jan-10-22 04:15PM  
Jan-07-22 07:00PM  
Dec-21-21 08:30AM  
Dec-16-21 09:00AM  
Dec-10-21 08:56AM  
Nov-15-21 03:48PM  
Nov-09-21 07:30AM  
Nov-04-21 03:01PM  
Nov-02-21 05:35PM  
Oct-29-21 10:27AM  
Oct-26-21 07:30AM  
Oct-08-21 04:50PM  
Sep-02-21 07:30AM  
Sep-01-21 07:30AM  
Aug-26-21 07:31AM  
Aug-18-21 11:47AM  
Aug-17-21 06:03PM  
Aug-16-21 04:30PM  
Aug-13-21 07:30AM  
Aug-11-21 08:52AM  
Aug-06-21 08:21AM  
Aug-03-21 05:45PM  
Jul-30-21 12:47PM  
Jul-27-21 03:03PM  
Jul-24-21 06:37AM  
Jul-14-21 07:30AM  
Jun-29-21 02:50PM  
Jun-21-21 07:41AM  
May-26-21 07:30AM  
May-14-21 07:30AM  
May-05-21 06:25PM  
Apr-28-21 07:30AM  
Apr-20-21 06:46AM  
Apr-16-21 06:25PM  
Apr-14-21 09:04AM  
Apr-13-21 04:02PM  
Apr-07-21 07:30AM  
Mar-11-21 07:30AM  
Mar-02-21 11:51PM  
Feb-23-21 07:30AM  
Feb-21-21 07:21AM  
Feb-18-21 12:40PM  
Jan-29-21 02:45PM  
Jan-22-21 01:36PM  
Jan-11-21 07:30AM  
Jan-07-21 07:30AM  
Dec-21-20 08:55AM  
Dec-19-20 10:40PM  
Dec-15-20 02:51AM  
Dec-04-20 07:30AM  
Nov-23-20 07:30AM  
Nov-17-20 07:30AM  
Nov-10-20 07:30AM  
Nov-09-20 08:07AM  
Nov-06-20 03:01PM  
Nov-05-20 06:35PM  
Oct-29-20 07:30AM  
Oct-14-20 01:47PM  
Oct-09-20 07:30AM  
Oct-02-20 12:26PM  
Sep-18-20 10:52AM  
Sep-17-20 09:46AM  
Sep-09-20 07:30AM  
Sep-02-20 07:30AM  
Aug-27-20 01:09PM  
Aug-21-20 07:30AM  
Aug-05-20 11:48AM  
Aug-04-20 06:35PM  
Jul-28-20 12:33PM  
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.